Our verdict is Uncertain significance. Variant got 1 ACMG points: 3P and 2B. PM2PP2BP4_Moderate
The NM_018896.5(CACNA1G):āc.59T>Cā(p.Met20Thr) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000217 in 1,385,040 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (ā ).
CACNA1G (HGNC:1394): (calcium voltage-gated channel subunit alpha1 G) Voltage-sensitive calcium channels mediate the entry of calcium ions into excitable cells, and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division, and cell death. This gene encodes a T-type, low-voltage activated calcium channel. The T-type channels generate currents that are both transient, owing to fast inactivation, and tiny, owing to small conductance. T-type channels are thought to be involved in pacemaker activity, low-threshold calcium spikes, neuronal oscillations and resonance, and rebound burst firing. Many alternatively spliced transcript variants encoding different isoforms have been described for this gene. [provided by RefSeq, Sep 2011]
Verdict is Uncertain_significance. Variant got 1 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP2
Missense variant in gene, where missense usually causes diseases (based on misZ statistic), CACNA1G. . Gene score misZ 4.6386 (greater than the threshold 3.09). Trascript score misZ 5.0317 (greater than threshold 3.09). GenCC has associacion of gene with intellectual disability, spinocerebellar ataxia type 42, spinocerebellar ataxia 42, early-onset, severe, with neurodevelopmental deficits.
BP4
Computational evidence support a benign effect (MetaRNN=0.09073618).
Uncertain significance, criteria provided, single submitter
clinical testing
GeneDx
Apr 25, 2022
Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge -
Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);Gain of phosphorylation at M20 (P = 0.0093);